| scholarly article | Q13442814 |
| P2093 | author name string | Keith R McCrae | |
| Shruti Chaturvedi | |||
| P2860 | cites work | Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant | Q85743774 |
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases | Q86704919 | ||
| New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome | Q87417887 | ||
| Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 | ||
| Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant | Q24247000 | ||
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator | Q28193764 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation | Q33375186 | ||
| Prevention of murine antiphospholipid syndrome by BAFF blockade | Q33380975 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. | Q33504706 | ||
| Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. | Q33576496 | ||
| Epidemiology of the antiphospholipid antibody syndrome | Q33916234 | ||
| Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression | Q34003992 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study | Q34619943 | ||
| CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis | Q35746486 | ||
| Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies | Q35977256 | ||
| Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) | Q36242479 | ||
| Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome | Q36890849 | ||
| Pediatric antiphospholipid antibodies and antiphospholipid syndrome | Q37249533 | ||
| Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome | Q37473270 | ||
| A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients | Q37702168 | ||
| Challenges in the diagnosis of the antiphospholipid syndrome | Q37723113 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Antiphospholipid antibodies--we are not quite there yet. | Q37829519 | ||
| Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review | Q38113968 | ||
| Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab | Q38115382 | ||
| Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives | Q38182509 | ||
| Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review | Q38392607 | ||
| Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study | Q39138695 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants | Q43463817 | ||
| The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic | Q43533979 | ||
| Recent guidelines and recommendations for laboratory detection of lupus anticoagulants | Q43594150 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin | Q45220126 | ||
| Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". | Q45780878 | ||
| The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. | Q45967639 | ||
| Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome | Q47225448 | ||
| Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin | Q47868175 | ||
| The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. | Q53189388 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients | Q57907773 | ||
| Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation | Q58048140 | ||
| Rivaroxaban and false positive lupus anticoagulant testing | Q60619095 | ||
| Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies | Q61853563 | ||
| Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA | Q78321143 | ||
| Lupus anticoagulants and the risk of a first episode of deep venous thrombosis | Q81064718 | ||
| Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time | Q84349009 | ||
| The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study | Q84438431 | ||
| An international multicentre‐laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti‐beta2‐glycoprotein autoantibodies | Q85100865 | ||
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 53-60 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | The antiphospholipid syndrome: still an enigma | |
| P478 | volume | 2015 |
| Q36303250 | Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant |
| Q38827909 | Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q49968681 | Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome |
| Q90241448 | Neutrophil Extracellular Traps, Antiphospholipid Antibodies and Treatment |
| Q36867309 | Neutrophil extracellular traps - the dark side of neutrophils |
| Q58551653 | Obstetric antiphospholipid syndrome |
| Q59791491 | Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome |
Search more.